- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02471495
RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)
A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect With Mitomycin C in Non-Muscle Invasive Bladder Cancer Patients With BCG-refractory CIS
Study Overview
Detailed Description
The study will consist of three periods: 1) Screening; 2) Induction, and 3) Maintenance treatment and follow-up.
Screening period After signing informed consent, patients will be screened for study eligibility by assessment of inclusion and exclusion criteria. Screening procedures will include collection of demographic data, medical history, physical examination, vital signs, and laboratory evaluations.
Induction period Patients will receive 8 weekly treatments of RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).
Maintenance Treatment and Follow-up Period
During the maintenance period, patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment, unless the patient's participation in the study is terminated due to either:
- a lack of complete response (at 6 months) or worsening of disease (at 3 months; see first and second follow-up control below), or
- recurrence/progression Patients will be assessed by cystoscopy, urine cytology and, if required, subsequent biopsy or transurethral resection (TUR) of suspect areas every 3 months till the end of the study.
Two consecutive definite positive urine cytologies will be required to confirm persistent or recurrent disease if visual and biopsy are negative. In such cases, investigation of extravesical locations (CT-IVU, prostatic urethra biopsy) will be performed between the first and second urine cytology.
At the first follow-up control, i.e., 3 months after administration of the first study treatment, patients will undergo a cystoscopy evaluation.
Patients failing to achieve a disease-free state at the time of the first follow-up will continue in the study, unless a new occurrence of a T1 and/or high-grade lesion is found or any extra-bladder involvement is evident from pathological analysis.
At the second, i.e., 6-month, follow-up visit, patients will undergo biopsies of suspicious areas and random bladder biopsies of the trigone, bladder dome, right, left, anterior and posterior of the bladder wall. Upper tract washes will be performed in patients in whom urine cytology will be positive with no pathological evidence of NMIBC lesions in the bladder or the prostatic urethra. Patients failing to achieve a disease-free state at the time of the 6 month assessment and/or experiencing a new disease occurrence, demonstrated by cystoscopy and biopsy, and/or in whom extra-bladder involvement is suggested by a positive upper tract washes result will be removed from the study.
Upper tract imaging (CT-IVU imaging is recommended, IVU if CT not available) will be performed at 12 months from the first study treatment.
Extended treatment and follow-up period For longer-term disease-free-survival data collection purposes, patients free of tumor at the end of the study will be offered to continue receiving one Synergo® RITE + MMC treatment every 8 weeks. Each such treatment will last about 60 minutes and will consist of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection, each cycle. These treatments will be given until the end of 24 months after the patient's first induction treatment. See table 2 for details on the extended treatment and follow-up.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with CIS, with or without coexisting papillary NMIBC, who either:
- fail to achieve a disease-free status by 6 months after initial BCG therapy, with maintenance or re-induction at 3 months due to either persistent or rapidly recurrent disease, or
- experience a worsening in NMIBC state following initial BCG therapy presenting with a new NMIBC instance, other than TaLG.
- All clinical, intra-operative and pathological items for the EAU risk stratification must be documented including a bladder map.
Patients with papillary disease must have undergone a repeat TUR:
- if the initial TUR was incomplete.
- if there was no muscle in the specimen after the initial TUR (except in TaLG tumors).
- in all T1 tumors. TUR of T1 sites must include muscle.
- in all HG tumors > 3cm.
- CT-IVU or IVU confirmation of absence of tumor(s) in the upper tract, kidney and ureters performed within 6 months before the treatment initiation in selected cases as recommended in latest EAU guidelines published prior to screening. If IVU protocol not available or contrast allergy/poor renal function preclude such imaging, then non-contrast CT or MRI of the abdomen/pelvis within the same timeframe will suffice.
- Visual inspection to exclude urothelial carcinoma (UC) in the urethra during cystoscopy.
Biopsy of the prostatic urethra in male patients prior to recruitment to exclude UC of the prostatic urethra, in patients with:
- tumor of trigone,
- tumor of bladder neck, or
- abnormal prostatic urethra
- All patients must have urine cytology collected from either voided urine or bladder wash within the screening period prior to recruitment.
- All patients must have prostatic urethral biopsies collected within the screening period prior to recruitment.
- Age ≥ 18 yrs.
- Normal kidneys and ureters.
Pre-treatment hematology and biochemistry values within the limits:
- Hemoglobin ≥ 10 g/dl
- Platelets ≥ 150 x 10^9/L
- WBC ≥ 3.0 x 10^9/L
- ANC ≥ 1.5 x 10^9/L
- Serum creatinine < 1.5 x ULN
- SGOT < 1.5 x ULN
- SGPT < 1.5 x ULN
- Alkaline phosphatase < 1.5 x ULN
- Negative pregnancy test for women of childbearing potential.
- A life expectancy at least of the duration of the study (up to 13 months).
- Patients unfit or unwilling to have a full or partial (if appropriate) cystectomy.
- Signed informed consent.
Exclusion Criteria:
- Non-UC tumor of the urinary tract.
- Upper tract and intramural tumors (e.g., in ostium).
- Positive selective cytology from the upper tract.
- History of stage > T1 UC.
- Papillary tumor in repeat TUR in patients diagnosed with HG > 3cm and/or T1 in the initial TUR.
- Papillary tumor ≥ T1 in repeat TUR
- Known or suspected reduced bladder capacity. Patients will have a US estimation of maximum bladder capacity or void spontaneously the maximum they can retain in their bladder, and this will be used to determine urine volume. A minimum volume of 250 ml is required.
- Bleeding disorder.
- Macrohematuria of ≥ 250 RBC/uL or equivalent (e.g., > "+++" erythrocytes in a dipstick analysis) within 4 weeks before treatment start.
- Lactating women.
- Women of childbearing potential unwilling or unable to use adequate contraception if sexually active.
- More than a maintenance dose of oral corticosteroids (maintenance dose is defined as the same dose regimen over the past 6 months for a condition requiring continual corticosteroid treatment) or patients with an immunocompromised state for any reason.
- More than low-dose methotrexate (>17.5 mg once a week).
- Other malignancy within the past 5 years, except: non-melanomatous skin cancer cured by excision, surgically treated carcinoma in situ of the cervix or ductal CIS (DCIS)/lobular CIS (LCIS) of the breast or stable prostate cancer (under active surveillance or hormone control) with a life expectancy of more than 5 years.
- Any known allergy (e.g., to MMC) or adverse event that would prevent a prospective study participant from receiving the study treatment.
- Known untreated urethral strictural disease or bladder neck contracture or any other condition that may prevent catheterization with 21F catheter. Patients may undergo dilation or urethral incision before entering the study.
- Bladder diverticula with cumulative diameter > 1cm or tumor in a diverticulum.
- UTI at any time within 4 weeks before treatment start.
- Significant urinary incontinence (spontaneous, requiring use of pads).
- History of pelvic irradiation.
- Patients with implanted electronic devices (such as cardiac pacemakers) unless they receive permission from their treating physician (e.g., cardiologist) and are monitored by a treating physician during the treatment session.
- Participation in another study, unless discussed with and approved by the study manager.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Synergo® RITE + MMC
Induction Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment). Maintenance Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment. |
Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter. MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-free survival
Time Frame: 12 months
|
The study will be deemed successful if the recurrence-free survival probability after 12 months is at least 30%.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response Rate (CRR)
Time Frame: 6 months after first treatment
|
A satisfactory outcome will be if the CRR at 6 months is at least 40%.
|
6 months after first treatment
|
Rate of serious adverse events
Time Frame: 12 months
|
12 months
|
|
Proportion of patients who discontinue treatment for safety reasons.
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Igal Ruvinsky, PhD, Medical Enterprises
- Principal Investigator: Shariat Shahrokh, Prof. med, Medical University Vienna, General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RITE-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
Clinical Trials on Synergo® RITE + MMC
-
Medical Enterprises Europe B.V.TerminatedNeoplasms | Urologic Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Urinary Bladder Cancer | Malignant Tumor of Urinary BladderAustria, Israel, Italy, Netherlands
-
Medical Enterprises Europe B.V.WithdrawnNeoplasms | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms
-
Medical Enterprises Ltd.TerminatedUrinary Bladder Cancer | Bladder Cancer | Malignant Tumor of Urinary Bladder | Bladder Neoplasm | Cancer of Bladder | Carcinoma in Situ of Bladder | Bladder Tumors | Cancer of the Bladder | Neoplasms, Bladder | Papillary Carcinoma of Bladder (Diagnosis) | BCG-Unresponsive Bladder CancerUnited States
-
Hill-RomCompletedPressure UlcersUnited States
-
Centre Hospitalier Universitaire, AmiensUnknownObesity | Central Venous CathetersFrance
-
Rennes University HospitalÉcole Normale Supérieure de CachanCompletedStroke | HemiplegiaFrance
-
Merck Sharp & Dohme LLCRecruitingUrinary Bladder NeoplasmsUnited States, Australia, Czechia, Estonia, France, Guatemala, Hungary, Israel, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Turkey, Ukraine, United Kingdom, Denmark, ... and more